These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 21472249)

  • 1. Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review).
    Grüngreiff K; Reinhold D
    Mol Med Rep; 2010; 3(3):371-5. PubMed ID: 21472249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunology of hepatitis C: clinical significance of T cell response].
    Shin EC
    Korean J Hepatol; 2006 Jun; 12(2):140-53. PubMed ID: 16804339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant.
    Kamar N; Ribes D; Izopet J; Rostaing L
    Transplantation; 2006 Oct; 82(7):853-6. PubMed ID: 17038897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunopathology of chronic liver diseases].
    Meyer zum Büschenfelde KH
    Verh Dtsch Ges Pathol; 1995; 79():186-97. PubMed ID: 8600684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hepatitis C virus infection in patients with end-stage renal disease.
    Liu CH; Kao JH
    J Gastroenterol Hepatol; 2011 Feb; 26(2):228-39. PubMed ID: 21261711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of interleukin-8 in hepatitis C virus infection: relation to combined peg-interferon ribavirin response and genotype 4.
    El Sayed ZM; Mansour FA; Ghal MF; Abou-Zahra SB
    Immunol Invest; 2011; 40(1):29-38. PubMed ID: 20809700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.
    Nelson DR; Marousis CG; Ohno T; Davis GL; Lau JY
    Hepatology; 1998 Jul; 28(1):225-30. PubMed ID: 9657116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatitis C virus infection in renal diseases: state of knowledge, therapeutic problems and perspectives].
    Stachowski J
    Pol Merkur Lekarski; 2000 Apr; 8(46):303-6. PubMed ID: 10897663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
    Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
    Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-based therapy for chronic hepatitis C.
    Chang DY; Shin EC
    J Leukoc Biol; 2009 Jul; 86(1):33-9. PubMed ID: 19395471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.